# NovoCure Limited (NVCR) · Edgar & Edgarette company card

> NovoCure Limited (NVCR) grew revenue 8.3% in FY2025 to $655 million, operating margin -23.5% against a 1.2% median for surgical & medical instruments & apparatus, equity 42.3% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1645113 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/NVCR) · [JSON](https://www.pops4.com/boards/company/NVCR.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $655M |
| Revenue growth, 1 year | 8.3% |
| Revenue growth per year | 5.2% |
| Operating margin | -23.5% (prior year -28.2%) |
| Net margin | -20.8% |
| Operating cash flow | −$49M |
| Capital spending | $27M |
| Free cash flow | −$76M |
| Cash | $94M |
| Long-term debt | $195M |
| Total assets | $804M |
| Total equity | $340M |
| Equity ÷ assets | 42.3% |
| Return on equity | -40.0% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -2.29 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Beneish M: -2.24 (below the −1.78 line)
- Health Harbor boat: Weathered boat · two warning signs · operating cash flow was negative; operating loss: a margin of -23.5% in FY2025
- Cash Compass: In between · no clear cash pattern yet

## Edgarette's reading

Exposure: revenue $655.4M (FY2025), total debt $195.0M. Experience: revenue up 8.3% on the year, up 5.2% a year over 4 years; operating margin -23.5%, up from -28.2%. Soundness: equity 42.3% of assets, return on equity -40.0%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $586.4M and $814.2M next year (method v4.1: its own 4-year record of growth weighed at 50% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $539.7M to $887.7M. A statistical range, not company guidance. Against peers (60 filers, $50M+ revenue, surgical & medical instruments & apparatus): operating margin -23.5% against a 1.2% median; growth 8.3% against 11.6%.

Range logged 2026-09-25, receipt db2b0366d41f585a, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 4, latest 2026-09-09 ([filing](https://www.sec.gov/Archives/edgar/data/1645113/000164511326000068/0001645113-26-000068-index.htm))

## Recent filings

- 8-K · filed 2026-10-29 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1645113/000164511326000081/0001645113-26-000081-index.htm)
- 10-Q · filed 2026-10-29 · [filing](https://www.sec.gov/Archives/edgar/data/1645113/000164511326000080/0001645113-26-000080-index.htm)
- 8-K · filed 2026-10-01 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1645113/000164511326000071/0001645113-26-000071-index.htm)
- 8-K · filed 2026-09-09 · 5.02 Departure or Election of Directors; Appointment of Officers; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1645113/000164511326000068/0001645113-26-000068-index.htm)
- 8-K · filed 2026-09-01 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1645113/000164511326000065/0001645113-26-000065-index.htm)
- 8-K · filed 2026-07-23 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1645113/000164511326000063/0001645113-26-000063-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001645113.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1645113

## Cite

POPS4, Edgar & Edgarette: NovoCure Limited (NVCR) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/NVCR. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.